Business Development

Why Partner With Us

We have a track-record of successful scientific and development collaborations that demonstrate speed, collaboration, innovation, and strong partner relationships.

We have collaborated with partners to acquire the rights to five compounds currently in development and are keenly interested in continuing to acquire and develop novel, differentiated programs and platforms.

What We’re Focused On

We are focused on building a differentiated portfolio of transformational therapeutics for patients with serious and life-threatening diseases. We focus on a number of therapeutic disease areas, drug platforms and technologies.


  • Large and small molecules with differentiated efficacy for the treatment of autoimmune and autoinflammatory conditions
  • Application of innovative approaches (e.g., Chimeric Auto-antigen Receptor-T cells or Gene Therapy) to autoimmune and autoinflammatory conditions
  • Tolerance induction
  • Local application of systemically validated mechanisms
  • Biomarker-based approaches to stratifying patients within larger heterogeneous diseases
  • Combination therapeutics


  • Large and small molecules with the potential for differentiated efficacy for the treatment of orphan/niche cardiovascular diseases
  • Innovative approaches orphan/niche cardiovascular diseases


  • Anti-pruritic therapeutics
  • Application of innovative approaches to treat various skin diseases (e.g., gene therapy)
  • Large and small molecules with differentiated efficacy for the treatment of dermatological conditions (outside of immunomodulatory approaches)


  • Highly-differentiated discovery platforms
  • Rapid development potential from concept to IND
  • Bioinformatic approaches to identify potential disease targets or responder populations